Evelo Biosciences, Inc.
Evelo Biosciences, Inc. (EVLO): 2 pipeline candidates · ~5 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.3 months
D/E -1.77 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for Evelo Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2K
Cash
$18.1M
Quarterly Burn
$10.4M
Runway
5.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Evelo Biosciences, Inc.'s pipeline?
Evelo Biosciences, Inc. (EVLO) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Evelo Biosciences, Inc.'s lead drug candidate?
Evelo Biosciences, Inc.'s most advanced tracked candidate is edp1815 (Phase 2) for psoriasis and atopic dermatitis.
What is Evelo Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Evelo Biosciences, Inc. has approximately 5.3 months of cash runway.
What is Evelo Biosciences, Inc.'s market capitalization?
Evelo Biosciences, Inc.'s market capitalization is approximately $2K.
Who is the CEO of Evelo Biosciences, Inc.?
Flagship Opportunities is the chief executive officer of Evelo Biosciences, Inc. (EVLO).
Get the full picture on Evelo Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.